Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.

NCT06914128 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06914128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06914128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 21, 2025
Completion date
June 18, 2029
Enrollment
450 (estimated)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

mtap-deleted solid tumors